Skip to main content
Erschienen in: Pediatric Cardiology 3/2024

30.03.2023 | Research

Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy?

verfasst von: Kothandam Sivakumar, Gaurav Jain

Erschienen in: Pediatric Cardiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Surgical myectomy is recommended for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) after optimal pharmacological therapy. Percutaneous transluminal septal myocardial ablation (PTSMA) is reserved for high-risk adults. Symptomatic patients below 25 years underwent either surgery or PTSMA after heart-team discussion and informed consent. Echocardiography assessed gradients in surgical group. PTSMA group underwent invasive transseptal hemodynamic assessment, selective coronary angiography and super-selective cannulation of septal perforators using microcatheters. Contrast echocardiography through the microcatheter identified the myocardial target for PTSMA. Hemodynamic and electrocardiographic monitoring guided alcohol injection. Both groups were continued on beta-blockers. Symptoms, echocardiographic gradients and Brain natriuretic peptide (NTproBNP) measurements were assessed on follow-up. Twelve patients aged 5–23 years (11–98 kg) formed the study group. Indications for PTSMA in 8 patients included abnormal mitral valve anatomy warranting replacement (n = 3), Jehovah’s witness (n = 2), severe neurodevelopmental and growth retardation (n = 1) and refusal of surgery (n = 2). PTSMA targeted first perforator (n = 5), second perforator (n = 2) and anomalous septal artery from left main trunk (n = 1). Outflow gradient reduced from 92.5 ± 19.7 to 33.1 ± 13.5 mmHg. At a median follow-up of 38 months (range 3–120 weeks), the peak instantaneous echocardiographic gradient was 32 ± 16.5 mmHg. Gradient reduced in four surgical patients from 86.5 ± 16.3 mmHg to 42 ± 14.7 mm Hg. All patients were in NYHA class I/II on follow-up. The mean NTproBNP in PTSMA group reduced from 6084 ± 3628 pg/ml to 3081 ± 2019 pg/ml; it was 1396 and 1795 pg/ml in surgery. PTSMA may be considered in medically refractory high-risk young patients. It relieves symptoms and reduces gradient. Though surgery is preferred in young patients, PTSMA may have a role in selected patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al (2014) ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al (2014) ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed
2.
Zurück zum Zitat Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation 115:773–781CrossRefPubMed Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation 115:773–781CrossRefPubMed
3.
4.
Zurück zum Zitat Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM et al (2013) Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 382:1889–1897CrossRefPubMedPubMedCentral Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM et al (2013) Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 382:1889–1897CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Maron BJ, Spirito P, Wesley Y, Arce J (1986) Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 315:610–614CrossRefPubMed Maron BJ, Spirito P, Wesley Y, Arce J (1986) Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 315:610–614CrossRefPubMed
6.
Zurück zum Zitat Maron BJ, Roberts WC, Edwards JE, McAllister HA Jr, Foley DD, Epstein SE (1978) Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol 41:803–810CrossRefPubMed Maron BJ, Roberts WC, Edwards JE, McAllister HA Jr, Foley DD, Epstein SE (1978) Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol 41:803–810CrossRefPubMed
7.
Zurück zum Zitat Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK (2007) Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy-the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 4:503–512CrossRefPubMed Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK (2007) Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy-the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 4:503–512CrossRefPubMed
8.
Zurück zum Zitat Kunkala MR, Schaff HV, Nishimura RA et al (2013) Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg 96:564–570CrossRefPubMed Kunkala MR, Schaff HV, Nishimura RA et al (2013) Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg 96:564–570CrossRefPubMed
9.
Zurück zum Zitat Iacovoni A, Spirito P, Simon C et al (2012) A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J 33:2080–7CrossRefPubMedPubMedCentral Iacovoni A, Spirito P, Simon C et al (2012) A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J 33:2080–7CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kim LK, Swaminathan RV, Looser P et al (2016) Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol 1:324–332CrossRefPubMed Kim LK, Swaminathan RV, Looser P et al (2016) Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol 1:324–332CrossRefPubMed
11.
Zurück zum Zitat Kwon DH, Kapadia SR, Tuzcu EM et al (2008) Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc Interv 1:432–438CrossRefPubMed Kwon DH, Kapadia SR, Tuzcu EM et al (2008) Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc Interv 1:432–438CrossRefPubMed
12.
Zurück zum Zitat Fernandes VL, Nielsen C, Nagueh SF et al (2008) Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv 1:561–570CrossRefPubMed Fernandes VL, Nielsen C, Nagueh SF et al (2008) Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv 1:561–570CrossRefPubMed
13.
Zurück zum Zitat Veselka J, Faber L, Jensen MK, Cooper R, Januska J, Krejci J et al (2018) Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 34:16–22CrossRefPubMed Veselka J, Faber L, Jensen MK, Cooper R, Januska J, Krejci J et al (2018) Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 34:16–22CrossRefPubMed
14.
Zurück zum Zitat Gersh BJ, Maron BJ, Bonow RO et al (2011) ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142:1303–1338CrossRefPubMed Gersh BJ, Maron BJ, Bonow RO et al (2011) ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142:1303–1338CrossRefPubMed
15.
Zurück zum Zitat Holmes DR Jr, Valeti US, Nishimura RA (2005) Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv 66:375–389CrossRefPubMed Holmes DR Jr, Valeti US, Nishimura RA (2005) Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv 66:375–389CrossRefPubMed
16.
Zurück zum Zitat Veselka J, Zemanek D, Tomasov P et al (2009) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels 24:27–31CrossRefPubMed Veselka J, Zemanek D, Tomasov P et al (2009) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels 24:27–31CrossRefPubMed
17.
Zurück zum Zitat Leonardi RA, Kransdorf EP, Simel DL et al (2010) Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 3:97–104CrossRefPubMed Leonardi RA, Kransdorf EP, Simel DL et al (2010) Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 3:97–104CrossRefPubMed
18.
Zurück zum Zitat Alam M, Dokainish H, Lakkis NM (2009) Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 30:1080–1087CrossRefPubMed Alam M, Dokainish H, Lakkis NM (2009) Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 30:1080–1087CrossRefPubMed
19.
Zurück zum Zitat Olivotto I, Ommen SR, Maron MS et al (2007) Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial? J Am Coll Cardiol 50:831–834CrossRefPubMed Olivotto I, Ommen SR, Maron MS et al (2007) Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial? J Am Coll Cardiol 50:831–834CrossRefPubMed
20.
Zurück zum Zitat Nishimura RA, Ommen SR (2010) Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. Circ Cardiovasc Interv 3:91–93CrossRefPubMed Nishimura RA, Ommen SR (2010) Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. Circ Cardiovasc Interv 3:91–93CrossRefPubMed
21.
Zurück zum Zitat Seggewiss H, Rigopoulos A (2003) Management of hypertrophic cardiomyopathy in children. Paediatr Drugs 5:663–672CrossRefPubMed Seggewiss H, Rigopoulos A (2003) Management of hypertrophic cardiomyopathy in children. Paediatr Drugs 5:663–672CrossRefPubMed
22.
Zurück zum Zitat Lawin D, Lawrenz T, Radke K, Stellbrink C (2022) Safety and efficacy of alcohol septal ablation in adolescents and young adults with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 111:207–217CrossRefPubMed Lawin D, Lawrenz T, Radke K, Stellbrink C (2022) Safety and efficacy of alcohol septal ablation in adolescents and young adults with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 111:207–217CrossRefPubMed
24.
Zurück zum Zitat Marino B, Digilio MC, Toscano A et al (1999) Congenital heart disease in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135:703–706CrossRefPubMed Marino B, Digilio MC, Toscano A et al (1999) Congenital heart disease in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135:703–706CrossRefPubMed
25.
26.
Zurück zum Zitat Fifer MA (2018) Septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 72:3095–3097CrossRefPubMed Fifer MA (2018) Septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 72:3095–3097CrossRefPubMed
27.
Zurück zum Zitat Liebregts M, Faber L, Jensen MK et al (2017) Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol Intv 10:1134–1143CrossRef Liebregts M, Faber L, Jensen MK et al (2017) Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol Intv 10:1134–1143CrossRef
28.
Zurück zum Zitat Cano MN, Fortunato de Cano SJ, Sousa JEMR (2010) Alcohol septal ablation after myomectomy failure—solutions for unusual cases. Catheter Cardiovasc Interv 76:719–723CrossRefPubMed Cano MN, Fortunato de Cano SJ, Sousa JEMR (2010) Alcohol septal ablation after myomectomy failure—solutions for unusual cases. Catheter Cardiovasc Interv 76:719–723CrossRefPubMed
29.
Zurück zum Zitat Kimmelsteil C (2010) Alcohol septal ablation in young children: addressing large gradients in little people. Catheter Cardiovasc Interv 76:724–725CrossRef Kimmelsteil C (2010) Alcohol septal ablation in young children: addressing large gradients in little people. Catheter Cardiovasc Interv 76:724–725CrossRef
30.
Zurück zum Zitat Emmel M, Sreeram N, de Giovanni JV et al (2005) Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol 94:699–703CrossRefPubMed Emmel M, Sreeram N, de Giovanni JV et al (2005) Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol 94:699–703CrossRefPubMed
31.
Zurück zum Zitat Teo EP, Teoh JG, Hung J (2015) Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol 30:475–482CrossRefPubMed Teo EP, Teoh JG, Hung J (2015) Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol 30:475–482CrossRefPubMed
32.
Zurück zum Zitat Carvalho JL, Schaff HV, Morris CS et al (2022) Anomalous papillary muscles-Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 163:83-89.e1CrossRef Carvalho JL, Schaff HV, Morris CS et al (2022) Anomalous papillary muscles-Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 163:83-89.e1CrossRef
33.
Zurück zum Zitat Marinakis S, Van der Linden P, Tortora R et al (2016) Outcomes from cardiac surgery in Jehovah’s witness patients: experience over twenty-one years. J Cardiothorac Surg 11:67CrossRefPubMedPubMedCentral Marinakis S, Van der Linden P, Tortora R et al (2016) Outcomes from cardiac surgery in Jehovah’s witness patients: experience over twenty-one years. J Cardiothorac Surg 11:67CrossRefPubMedPubMedCentral
Metadaten
Titel
Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy?
verfasst von
Kothandam Sivakumar
Gaurav Jain
Publikationsdatum
30.03.2023
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 3/2024
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-023-03145-6

Weitere Artikel der Ausgabe 3/2024

Pediatric Cardiology 3/2024 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.